5-((2-氯嘧啶丁-4-基)氨基)-2-甲基苯酚 | 1174166-56-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 5-((2-氯嘧啶丁-4-基)氨基)-2-甲基苯酚
• 英文名称: 2-chloro-4-(3-hydroxy-4-methylanilino)pyrimidine
• 英文别名: 5-((2-Chloropyrimidin-4-yl)amino)-2-methylphenol；5-[(2-chloropyrimidin-4-yl)amino]-2-methylphenol
• CAS: 1174166-56-3
• 化学式: C₁₁H₁₀ClN₃O
• 分子量: 235.673
• InChiKey: HVMFBRQDAFODKO-UHFFFAOYSA-N

物化性质

• 沸点：
  456.3±30.0 °C(Predicted)
• 密度：
  1.397±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  58
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-((2-氯嘧啶丁-4-基)氨基)-2-甲基苯酚 、 间溴苯胺 以 乙醇 为溶剂， 反应 16.0h， 以29%的产率得到2-(3-bromoanilino)-4-(3-hydroxy-4-methylanilino)pyrimidine hydrochloride
  参考文献：
  名称：

  Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor

  摘要：

  Inhibition of the vascular endothelial growth factor (VEGF) signaling pathway has emerged as one of the most promising new approaches for cancer therapy. We describe herein the key steps starting from an initial screening hit leading to the discovery of pazopanib, N(4)-(2,3-dimethyl-2H-indazol-6-yl)-N(4)-methyl-N(2)-(4-methyl-3-sulfonamidophenyl)-2,4-pyrimidinediamine, a potent pan-VEGF receptor (VEGFR) inhibitor under clinical development for renal-cell cancer and other solid tumors.

  DOI：

  10.1021/jm800566m
• 作为产物：
  描述：

  2,4-二氯嘧啶 、 5-氨基-2-甲基苯酚 在 碳酸氢钠 作用下， 以 乙醇 为溶剂， 反应 1.0h， 以73%的产率得到5-((2-氯嘧啶丁-4-基)氨基)-2-甲基苯酚
  参考文献：
  名称：

  Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor

  摘要：

  Inhibition of the vascular endothelial growth factor (VEGF) signaling pathway has emerged as one of the most promising new approaches for cancer therapy. We describe herein the key steps starting from an initial screening hit leading to the discovery of pazopanib, N(4)-(2,3-dimethyl-2H-indazol-6-yl)-N(4)-methyl-N(2)-(4-methyl-3-sulfonamidophenyl)-2,4-pyrimidinediamine, a potent pan-VEGF receptor (VEGFR) inhibitor under clinical development for renal-cell cancer and other solid tumors.

  DOI：

  10.1021/jm800566m

文献信息

• Discovery of 5-[[4-[(2,3-Dimethyl-2<i>H</i>-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor
  作者：Philip A. Harris、Amogh Boloor、Mui Cheung、Rakesh Kumar、Renae M. Crosby、Ronda G. Davis-Ward、Andrea H. Epperly、Kevin W. Hinkle、Robert N. Hunter、Jennifer H. Johnson、Victoria B. Knick、Christopher P. Laudeman、Deirdre K. Luttrell、Robert A. Mook、Robert T. Nolte、Sharon K. Rudolph、Jerzy R. Szewczyk、Anne T. Truesdale、James M. Veal、Liping Wang、Jeffrey A. Stafford

  DOI：10.1021/jm800566m

  日期：2008.8.1

  Inhibition of the vascular endothelial growth factor (VEGF) signaling pathway has emerged as one of the most promising new approaches for cancer therapy. We describe herein the key steps starting from an initial screening hit leading to the discovery of pazopanib, N(4)-(2,3-dimethyl-2H-indazol-6-yl)-N(4)-methyl-N(2)-(4-methyl-3-sulfonamidophenyl)-2,4-pyrimidinediamine, a potent pan-VEGF receptor (VEGFR) inhibitor under clinical development for renal-cell cancer and other solid tumors.